Necroptosis is an alternative cell death pathway different from the more familiar caspase-dependent apoptosis. It involves three kinases - RIPK1, MLKL and RIPK3 of which RIPK1 appears easiest to target. GSK has a RIPK1 compound in trials in IBD, so it has potential applications outside the CNS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.